JENA, Germany, December 11, 2025 — InflaRx N.V. announced that the World Health Organization (WHO) has granted the International Nonproprietary Name (INN) “izicopan” for its investigational oral C5aR inhibitor INF904, marking a key milestone in the drug’s advancement as a potential best-in-class therapy for inflammatory diseases including hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The newly assigned name will next appear in the WHO list of recommended INNs, reflecting global recognition of the compound’s identity and developmental maturity.
Science Significance
Scientifically, izicopan represents a significant advancement in complement-system modulation, designed as an orally administered, highly selective small-molecule inhibitor of the C5a receptor (C5aR1). Unlike earlier agents in this pathway, izicopan demonstrates minimal inhibition of CYP3A4/5, reducing the risk of drug–drug interactions that complicate treatment in patients frequently receiving glucocorticoids or other metabolic therapies. First-in-human results reported no safety signals of concern across a wide dosing range, and pharmacodynamic data confirmed ≥90% blockade of C5a-induced neutrophil activation, establishing strong mechanistic validation. Early Phase 2a data in HS and CSU show rapid and durable reductions in inflammatory lesions, robust HiSCR responses, and marked improvements in patient-reported disease severity—indicating that izicopan could deliver biologic-like efficacy in a convenient oral form.
Regulatory Significance
From a regulatory perspective, securing an INN is a major milestone toward future global submissions, enabling consistent naming across jurisdictions and supporting standardized labeling, safety reporting, and clinical documentation. The INN “izicopan” signals that WHO recognizes the drug’s distinct molecular identity and its readiness to progress through advanced clinical phases. For regulatory agencies, the consistent naming structure also streamlines pharmacovigilance tracking and risk-management frameworks as the molecule advances through clinical testing in HS, CSU, and other inflammatory indications. The clean safety data from early trials and izicopan’s differentiated pharmacokinetic profile further strengthen its regulatory footing as InflaRx prepares for later-stage development and potential engagement on expedited pathways for high-need dermatologic and autoimmune diseases.
Business Significance
Advertisement
Commercially, the naming milestone consolidates izicopan’s position as a key growth driver within InflaRx’s expanding anti-inflammatory portfolio. As an oral, small-molecule complement inhibitor, izicopan enables access to sizable markets where biologics remain costly or difficult to administer, including chronic inflammatory skin disorders with high prevalence and unmet need. The drug’s potential best-in-class profile, reinforced by strong pharmacodynamic performance and favorable tolerability, enhances its competitive differentiation in a rapidly evolving complement-therapeutics landscape. InflaRx’s established expertise in anti-C5a and anti-C5aR technologies, demonstrated through its monoclonal antibody vilobelimab, further strengthens izicopan’s commercial trajectory by leveraging shared scientific infrastructure and development experience. As izicopan progresses into later-stage studies, it may play a critical role in diversifying InflaRx’s revenue base and expanding its global partnering potential.
Patients’ Significance
For patients with HS, CSU, and other complement-mediated inflammatory diseases, izicopan represents a highly promising therapeutic alternative, particularly for those seeking effective oral options that avoid injection burden and offer improved safety compared with systemic immunosuppressants. Early evidence of reductions in abscesses, nodules, draining tunnels, and pain scores in HS patients suggests meaningful clinical benefit capable of improving day-to-day functioning and long-term quality of life. In CSU, substantial reductions in UAS7 scores and improvements in UCT7 disease-control measures reinforce the drug’s therapeutic potential, especially for individuals with severe disease unresponsive to current treatments. If later-stage results continue to validate its efficacy and safety, izicopan may offer a new modality for patients requiring fast-acting, durable, and well-tolerated anti-inflammatory therapy.
Policy Significance
At a policy level, the INN assignment emphasizes the importance of standardized drug nomenclature in global health systems, supporting transparency, safety surveillance, and international harmonization of pharmacological information. As complement-pathway therapeutics expand across indications, regulators and policymakers are increasingly focused on ensuring that novel agents integrate into clinical practice with clear risk-benefit communication. Izicopan’s oral delivery and differentiated safety profile may also influence broader policy discussions on accessibility and cost, especially as healthcare systems prepare to incorporate next-generation anti-inflammatory treatments. Its advancement reinforces the value of public-health frameworks that support innovation in immune-mediated disease management.
The WHO’s designation of “izicopan” marks a pivotal regulatory and scientific milestone for InflaRx as it advances its next-generation oral complement inhibitor through clinical development. With promising early data in both HS and CSU, a favorable safety profile, and strong mechanistic validation, izicopan stands positioned to become a significant therapeutic contender in inflammatory disease management. As InflaRx prepares for later-phase studies, this milestone underscores the drug’s growing global identity and its potential to reshape care for patients with chronic inflammatory disorders.
Source: InflaRx N.V. press release
